AtriCure Key Executives
This section highlights AtriCure's key executives, including their titles and compensation details.
Find Contacts at AtriCure
(Showing 0 of )
AtriCure Earnings
This section highlights AtriCure's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|---|---|---|---|---|
| Read Transcript | Q4 | 2024 | 2025-02-12 | $-0.23 | $-0.08 |
| Read Transcript | Q3 | 2024 | 2024-10-29 | $-0.20 | $-0.17 |
| Read Transcript | Q2 | 2024 | 2024-07-31 | N/A | N/A |
| Read Transcript | Q1 | 2024 | 2024-05-01 | $-0.21 | $-0.25 |
| Read Transcript | Q4 | 2023 | 2024-02-15 | $-0.22 | $-0.21 |
| Read Transcript | Q3 | 2023 | 2023-11-01 | $-0.30 | $-0.20 |
| Read Transcript | Q2 | 2023 | 2023-07-25 | $-0.27 | $-0.12 |
| Read Transcript | Q1 | 2023 | 2023-05-02 | $-0.34 | $-0.23 |
AtriCure, Inc. develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation. It also provides cryoICE Cryoablation System that enables the user to make linear ablations of varied lengths; EPi-Sense Guided Coagulation System, a single-use disposable device used for the treatment of symptomatic, drug-refractory, and long-standing persistent atrial fibrillation; AtriClip System, an implantable device coupled to a single-use disposable applier; and LARIAT System, a suture-based solution for soft-tissue closure compatible with a range of anatomical shapes. In addition, the company sells Lumitip Dissectors to separate tissues to provide access to key anatomical structures that are targeted for ablation; Glidepath guides for placement of clamps; Subtle Cannula's to support access for EPi-Sense catheters; and various reusable cardiac surgery instruments, which are used during surgical procedures for repair or replacement of certain heart valves. It markets and sells its products through independent distributors and direct sales personnel. The company was incorporated in 2000 and is headquartered in Mason, Ohio.
$31.31
Stock Price
$1.53B
Market Cap
1.30K
Employees
Mason, OH
Location
Financial Statements
Access annual & quarterly financial statements for AtriCure, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $465.31M | $399.25M | $330.38M | $274.33M | $206.53M |
| Cost of Revenue | $117.78M | $98.88M | $84.44M | $68.47M | $57.22M |
| Gross Profit | $347.52M | $300.37M | $245.94M | $205.86M | $149.31M |
| Gross Profit Ratio | 74.69% | 75.23% | 74.44% | 75.04% | 72.29% |
| Research and Development Expenses | $96.18M | $73.92M | $57.34M | $48.51M | $43.07M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $291.36M | $253.14M | $231.27M | $204.65M | $150.47M |
| Other Expenses | $- | $- | $-3.53M | $-4.82M | $-3.81M |
| Operating Expenses | $387.54M | $327.05M | $288.61M | $253.16M | $193.54M |
| Cost and Expenses | $505.32M | $425.93M | $373.05M | $321.62M | $250.76M |
| Interest Income | $4.43M | $3.79M | $1.99M | $466.00K | $1.10M |
| Interest Expense | $6.41M | $6.92M | $4.99M | $4.92M | $4.88M |
| Depreciation and Amortization | $18.73M | $14.81M | $11.71M | $10.44M | $9.55M |
| EBITDA | $-18.53M | $-8.11M | $-29.50M | $-36.85M | $-33.61M |
| EBITDA Ratio | -3.98% | -2.03% | -8.93% | -13.43% | -16.27% |
| Operating Income | $-40.01M | $-26.68M | $-42.67M | $-47.30M | $-44.23M |
| Operating Income Ratio | -8.60% | -6.68% | -12.92% | -17.24% | -21.42% |
| Total Other Income Expenses Net | $-3.66M | $-3.16M | $-3.53M | $-4.82M | $-3.81M |
| Income Before Tax | $-43.67M | $-29.85M | $-46.20M | $50.39M | $-48.04M |
| Income Before Tax Ratio | -9.39% | -7.48% | -13.98% | 18.37% | -23.26% |
| Income Tax Expense | $1.02M | $591.00K | $268.00K | $188.00K | $114.00K |
| Net Income | $-44.70M | $-30.44M | $-46.47M | $50.20M | $-48.16M |
| Net Income Ratio | -9.61% | -7.62% | -14.06% | 18.30% | -23.32% |
| EPS | $-0.95 | $-0.66 | $-1.02 | $1.11 | $-1.14 |
| EPS Diluted | $-0.95 | $-0.66 | $-1.02 | $1.09 | $-1.14 |
| Weighted Average Shares Outstanding | 47.10M | 46.31M | 45.74M | 45.07M | 42.12M |
| Weighted Average Shares Outstanding Diluted | 47.10M | 46.31M | 45.74M | 46.04M | 42.12M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $124.28M | $115.91M | $116.27M | $108.85M | $106.54M | $98.29M | $100.92M | $93.49M | $88.03M | $83.25M | $84.53M | $74.58M | $73.22M | $70.46M | $71.38M | $59.27M | $57.73M | $54.76M | $40.82M | $53.23M |
| Cost of Revenue | $31.66M | $29.12M | $30.18M | $28.32M | $27.47M | $24.42M | $23.84M | $23.89M | $22.91M | $21.53M | $21.01M | $18.98M | $18.20M | $18.23M | $17.30M | $14.73M | $15.29M | $14.42M | $13.17M | $14.34M |
| Gross Profit | $92.62M | $86.79M | $86.08M | $80.53M | $79.08M | $73.87M | $77.08M | $69.61M | $65.11M | $61.71M | $63.52M | $55.59M | $55.02M | $52.23M | $54.08M | $44.54M | $42.44M | $40.33M | $27.65M | $38.88M |
| Gross Profit Ratio | 74.53% | 74.88% | 74.04% | 73.98% | 74.22% | 75.15% | 76.38% | 74.45% | 73.97% | 74.13% | 75.14% | 74.55% | 75.14% | 74.12% | 75.76% | 75.14% | 73.52% | 73.66% | 67.74% | 73.06% |
| Research and Development Expenses | $34.96M | $20.96M | $19.66M | $19.84M | $20.80M | $20.35M | $17.44M | $15.33M | $13.75M | $15.17M | $14.79M | $13.63M | $13.81M | $11.28M | $12.20M | $11.22M | $10.87M | $10.58M | $10.04M | $11.59M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $49.07M | $33.75M | $24.90M | $42.75M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $72.19M | $73.24M | $73.60M | $71.60M | $66.95M | $61.60M | $63.78M | $60.06M | $55.50M | $57.27M | $62.39M | $56.12M | $53.71M | $49.87M | $56.96M | $49.21M | $49.07M | $33.75M | $24.90M | $42.75M |
| Other Expenses | $- | $- | $28.00K | $-82.00K | $9.00K | $-919.00K | $-881.00K | $-616.00K | $87.00K | $-1.50M | $-111.00K | $-93.00K | $-1.19M | $-1.52M | $-14.00K | $-1.00M | $-961.00K | $-962.00K | $29.00K | $-946.00K |
| Operating Expenses | $107.14M | $94.20M | $93.25M | $91.45M | $87.75M | $81.96M | $81.22M | $75.39M | $69.25M | $72.44M | $77.18M | $69.75M | $67.52M | $61.16M | $69.16M | $60.42M | $59.94M | $44.33M | $34.94M | $54.34M |
| Cost and Expenses | $138.80M | $123.31M | $123.44M | $119.77M | $115.21M | $106.38M | $105.06M | $99.28M | $92.16M | $93.97M | $98.19M | $88.73M | $85.72M | $79.39M | $86.45M | $75.16M | $75.23M | $58.75M | $48.11M | $68.68M |
| Interest Income | $1.20M | $1.28M | $997.00K | $952.00K | $1.04M | $915.00K | $961.00K | $875.00K | $1.43M | $370.00K | $76.00K | $116.00K | $112.00K | $117.00K | $103.00K | $134.00K | $187.00K | $246.00K | $263.00K | $405.00K |
| Interest Expense | $1.45M | $1.67M | $1.61M | $1.68M | $1.80M | $1.77M | $1.72M | $1.64M | $1.56M | $1.32M | $1.10M | $1.00M | $1.08M | $1.45M | $1.20M | $1.19M | $1.19M | $1.23M | $1.23M | $1.23M |
| Depreciation and Amortization | $4.83M | $4.93M | $4.53M | $4.45M | $4.18M | $4.11M | $3.58M | $2.94M | $2.92M | $2.99M | $2.94M | $2.87M | $2.83M | $2.83M | $2.66M | $2.12M | $2.17M | $2.48M | $2.46M | $2.44M |
| EBITDA | $-9.03M | $-936.00K | $-1.62M | $-6.96M | $-3.44M | $-3.12M | $274.00K | $-1.82M | $431.00K | $-7.92M | $-10.76M | $-11.26M | $-9.77M | $-6.10M | $-12.33M | $-13.57M | $-15.10M | $-1.24M | $-4.54M | $-12.73M |
| EBITDA Ratio | -7.26% | -0.81% | -1.39% | -6.39% | -3.23% | -3.18% | 0.27% | -1.95% | 0.49% | -9.51% | -12.73% | -15.10% | -13.35% | -8.66% | -17.27% | -22.90% | -26.16% | -2.27% | -11.11% | -23.91% |
| Operating Income | $-14.52M | $-7.41M | $-7.17M | $-10.92M | $-8.67M | $-8.09M | $-4.14M | $-5.78M | $-4.14M | $-10.72M | $-13.66M | $-14.15M | $-12.50M | $98.67M | $-15.08M | $-15.88M | $-17.50M | $-3.99M | $-7.29M | $-15.45M |
| Operating Income Ratio | -11.69% | -6.39% | -6.17% | -10.03% | -8.14% | -8.23% | -4.11% | -6.18% | -4.70% | -12.88% | -16.16% | -18.97% | -17.08% | 140.04% | -21.12% | -26.80% | -30.32% | -7.29% | -17.84% | -29.04% |
| Total Other Income Expenses Net | $-779.00K | $-126.00K | $-587.00K | $-2.17M | $-748.00K | $-919.00K | $-881.00K | $-616.00K | $87.00K | $-1.50M | $-1.14M | $-977.00K | $-1.19M | $-1.52M | $-1.11M | $-1.00M | $-961.00K | $-962.00K | $-939.00K | $-946.00K |
| Income Before Tax | $-15.30M | $-7.53M | $-7.75M | $-13.09M | $-9.42M | $-9.01M | $-5.03M | $-6.40M | $-4.05M | $-12.23M | $-14.80M | $-15.13M | $-13.69M | $97.15M | $-16.18M | $-16.89M | $-18.46M | $-4.95M | $-8.22M | $-16.40M |
| Income Before Tax Ratio | -12.31% | -6.50% | -6.67% | -12.02% | -8.84% | -9.16% | -4.98% | -6.84% | -4.60% | -14.69% | -17.50% | -20.28% | -18.69% | 137.87% | -22.68% | -28.49% | -31.99% | -9.05% | -20.15% | -30.81% |
| Income Tax Expense | $266.00K | $322.00K | $253.00K | $183.00K | $373.00K | $47.00K | $93.00K | $78.00K | $121.00K | $46.00K | $45.00K | $56.00K | $53.00K | $38.00K | $66.00K | $31.00K | $98.00K | $-4.00K | $12.00K | $8.00K |
| Net Income | $-15.57M | $-7.85M | $-8.01M | $-13.27M | $-9.79M | $-9.05M | $-5.12M | $-6.48M | $-4.17M | $-12.27M | $-14.84M | $-15.18M | $-13.74M | $97.11M | $-16.25M | $-16.92M | $-18.56M | $-4.95M | $-8.24M | $-16.41M |
| Net Income Ratio | -12.53% | -6.78% | -6.89% | -12.19% | -9.19% | -9.21% | -5.07% | -6.93% | -4.74% | -14.74% | -17.56% | -20.36% | -18.77% | 137.82% | -22.77% | -28.54% | -32.16% | -9.04% | -20.17% | -30.83% |
| EPS | $-0.33 | $-0.17 | $-0.17 | $-0.28 | $-0.21 | $-0.20 | $-0.11 | $-0.14 | $-0.09 | $-0.27 | $-0.32 | $-0.33 | $-0.30 | $2.15 | $-0.36 | $-0.38 | $-0.42 | $-0.11 | $-0.20 | $-0.42 |
| EPS Diluted | $-0.33 | $-0.17 | $-0.17 | $-0.28 | $-0.21 | $-0.20 | $-0.11 | $-0.14 | $-0.09 | $-0.27 | $-0.32 | $-0.33 | $-0.30 | $2.11 | $-0.36 | $-0.38 | $-0.42 | $-0.11 | $-0.20 | $-0.42 |
| Weighted Average Shares Outstanding | 47.10M | 47.10M | 46.91M | 46.72M | 46.45M | 46.41M | 46.27M | 46.11M | 45.91M | 45.45M | 45.69M | 45.53M | 45.29M | 45.26M | 45.03M | 44.63M | 44.04M | 44.01M | 41.65M | 38.67M |
| Weighted Average Shares Outstanding Diluted | 47.10M | 47.10M | 46.91M | 46.72M | 46.45M | 46.41M | 46.27M | 46.11M | 45.91M | 45.82M | 45.69M | 45.53M | 45.33M | 46.10M | 45.03M | 44.63M | 44.12M | 44.01M | 41.65M | 38.67M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $122.72M | $84.31M | $58.10M | $43.65M | $41.94M |
| Short Term Investments | $- | $52.98M | $63.01M | $75.44M | $202.27M |
| Cash and Short Term Investments | $122.72M | $137.28M | $121.11M | $119.09M | $244.22M |
| Net Receivables | $60.34M | $52.50M | $42.69M | $33.02M | $23.15M |
| Inventory | $75.33M | $67.90M | $45.93M | $38.96M | $35.03M |
| Other Current Assets | $9.43M | $8.56M | $5.48M | $5.00M | $4.35M |
| Total Current Assets | $267.83M | $266.25M | $215.21M | $196.08M | $306.74M |
| Property Plant Equipment Net | $47.39M | $46.76M | $42.62M | $36.17M | $30.20M |
| Goodwill | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M |
| Intangible Assets | $56.47M | $63.99M | $39.34M | $42.99M | $128.20M |
| Goodwill and Intangible Assets | $291.25M | $298.77M | $274.12M | $277.77M | $362.98M |
| Long Term Investments | $- | $- | $51.51M | $104.34M | $14.18M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.87M | $2.16M | $1.99M | $955.00K | $440.00K |
| Total Non-Current Assets | $341.50M | $347.69M | $370.23M | $419.24M | $407.80M |
| Other Assets | $- | $1 | $- | $- | $- |
| Total Assets | $609.33M | $613.93M | $585.45M | $615.31M | $714.54M |
| Account Payables | $25.03M | $27.35M | $19.90M | $18.60M | $12.74M |
| Short Term Debt | $2.81M | $2.53M | $2.14M | $1.76M | $6.67M |
| Tax Payables | $- | $- | $- | $1.45M | $1.26M |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $45.59M | $44.68M | $36.35M | $34.64M | $28.48M |
| Total Current Liabilities | $73.42M | $74.57M | $58.39M | $56.45M | $49.14M |
| Long Term Debt | $73.72M | $71.96M | $69.08M | $73.89M | $65.58M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.21M | $1.23M | $1.23M | $1.22M | $187.42M |
| Total Non-Current Liabilities | $74.94M | $73.19M | $70.30M | $75.11M | $253.01M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $148.36M | $147.76M | $128.69M | $131.56M | $302.14M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $49.00K | $48.00K | $47.00K | $46.00K | $45.00K |
| Retained Earnings | $-401.75M | $-357.06M | $-326.62M | $-280.15M | $-330.35M |
| Accumulated Other Comprehensive Income Loss | $-1.03M | $-993.00K | $-4.10M | $-948.00K | $312.00K |
| Other Total Stockholders Equity | $863.71M | $824.17M | $787.42M | $764.81M | $742.39M |
| Total Stockholders Equity | $460.97M | $466.17M | $456.75M | $483.76M | $412.39M |
| Total Equity | $460.97M | $466.17M | $456.75M | $483.76M | $412.39M |
| Total Liabilities and Stockholders Equity | $609.33M | $613.93M | $585.45M | $615.31M | $714.54M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $609.33M | $613.93M | $585.45M | $615.31M | $714.54M |
| Total Investments | $- | $52.98M | $114.52M | $179.77M | $216.45M |
| Total Debt | $76.53M | $74.49M | $69.08M | $75.65M | $74.00M |
| Net Debt | $-46.19M | $-9.82M | $10.98M | $31.99M | $32.06M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $122.72M | $130.34M | $106.03M | $64.97M | $84.31M | $80.60M | $67.24M | $77.34M | $58.10M | $48.82M | $54.56M | $28.14M | $43.65M | $39.89M | $67.62M | $85.38M | $41.94M | $33.38M | $88.52M | $21.77M |
| Short Term Investments | $- | $- | $7.99M | $40.99M | $52.98M | $52.42M | $59.78M | $58.52M | $63.01M | $73.82M | $63.90M | $83.26M | $75.44M | $79.86M | $92.25M | $141.82M | $202.27M | $199.69M | $143.98M | $46.77M |
| Cash and Short Term Investments | $122.72M | $130.34M | $114.02M | $105.96M | $137.28M | $133.01M | $127.03M | $135.86M | $121.11M | $122.64M | $118.45M | $111.40M | $119.09M | $119.75M | $159.87M | $227.21M | $244.22M | $233.07M | $232.50M | $68.54M |
| Net Receivables | $60.34M | $54.91M | $55.57M | $55.32M | $52.50M | $51.53M | $48.36M | $45.66M | $42.69M | $41.47M | $41.49M | $40.88M | $33.02M | $33.50M | $33.84M | $29.74M | $23.15M | $25.45M | $22.89M | $22.13M |
| Inventory | $75.33M | $76.55M | $73.65M | $71.94M | $67.90M | $61.89M | $55.41M | $48.85M | $45.93M | $43.95M | $41.29M | $40.76M | $38.96M | $38.59M | $37.61M | $36.14M | $35.03M | $34.33M | $32.81M | $32.06M |
| Other Current Assets | $9.43M | $7.50M | $9.61M | $12.00M | $8.56M | $6.28M | $7.18M | $7.96M | $5.48M | $8.44M | $9.86M | $13.14M | $10.00M | $7.75M | $9.27M | $10.43M | $4.35M | $6.74M | $7.67M | $8.59M |
| Total Current Assets | $267.83M | $269.29M | $252.85M | $245.22M | $266.25M | $252.72M | $237.97M | $238.32M | $215.21M | $212.28M | $206.17M | $199.61M | $196.08M | $195.71M | $235.94M | $298.30M | $306.74M | $296.21M | $292.03M | $127.02M |
| Property Plant Equipment Net | $47.39M | $49.64M | $46.20M | $46.23M | $46.76M | $45.44M | $44.89M | $44.21M | $42.62M | $42.52M | $40.29M | $37.38M | $36.17M | $32.37M | $32.86M | $29.25M | $30.20M | $31.45M | $32.81M | $36.06M |
| Goodwill | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M | $234.78M |
| Intangible Assets | $56.47M | $58.35M | $60.24M | $62.12M | $63.99M | $65.68M | $67.38M | $38.60M | $39.34M | $40.08M | $41.05M | $42.02M | $42.99M | $43.96M | $127.23M | $127.96M | $128.20M | $128.44M | $128.90M | $129.39M |
| Goodwill and Intangible Assets | $291.25M | $293.13M | $295.02M | $296.90M | $298.77M | $300.46M | $302.16M | $273.38M | $274.12M | $274.86M | $275.83M | $276.80M | $277.77M | $278.74M | $362.01M | $362.74M | $362.98M | $363.22M | $363.69M | $364.17M |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $7.60M | $25.56M | $51.51M | $51.41M | $64.30M | $70.51M | $104.34M | $105.10M | $69.77M | $9.13M | $14.18M | $16.52M | $15.34M | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $2.87M | $3.01M | $3.20M | $3.27M | $2.16M | $1.64M | $1.54M | $1.62M | $1.99M | $829.00K | $804.00K | $685.00K | $955.00K | $1.05M | $488.00K | $474.00K | $440.00K | $399.00K | $366.00K | $474.00K |
| Total Non-Current Assets | $341.50M | $345.78M | $344.42M | $346.40M | $347.69M | $347.55M | $356.20M | $344.77M | $370.23M | $369.63M | $381.22M | $385.38M | $419.24M | $417.26M | $465.13M | $401.60M | $407.80M | $411.58M | $412.20M | $400.71M |
| Other Assets | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $- | $- |
| Total Assets | $609.33M | $615.07M | $597.27M | $591.63M | $613.93M | $600.27M | $594.17M | $583.10M | $585.45M | $581.91M | $587.39M | $584.98M | $615.31M | $612.97M | $701.08M | $699.90M | $714.54M | $707.80M | $704.23M | $527.73M |
| Account Payables | $25.03M | $31.74M | $26.67M | $28.99M | $27.35M | $24.54M | $23.71M | $23.56M | $19.90M | $24.41M | $23.72M | $20.29M | $18.60M | $17.53M | $16.50M | $15.46M | $12.74M | $13.55M | $12.47M | $17.30M |
| Short Term Debt | $2.81M | $5.43M | $5.08M | $5.08M | $2.53M | $20.70M | $15.71M | $10.68M | $5.47M | $4.06M | $3.64M | $3.52M | $3.51M | $4.58M | $18.49M | $13.31M | $6.67M | $12.07M | $7.70M | $3.61M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.76M | $1.57M | $1.59M | $1.45M | $1.49M | $1.62M | $1.33M | $1.26M | $1.17M | $1.14M | $1.17M |
| Deferred Revenue | $- | $29.48M | $-58.68M | $- | $- | $- | $- | $- | $- | $- | $-1.82M | $- | $- | $1.49M | $1.62M | $1.33M | $1.26M | $1.17M | $1.14M | $1.17M |
| Other Current Liabilities | $45.59M | $7.79M | $29.48M | $27.18M | $44.68M | $37.29M | $31.99M | $28.23M | $33.02M | $27.37M | $27.38M | $21.97M | $32.88M | $30.36M | $30.83M | $28.37M | $28.48M | $17.96M | $16.75M | $16.98M |
| Total Current Liabilities | $73.42M | $74.43M | $61.23M | $61.25M | $74.57M | $82.54M | $71.41M | $62.47M | $58.39M | $57.60M | $56.32M | $47.38M | $56.45M | $53.95M | $67.43M | $58.46M | $49.14M | $44.75M | $38.05M | $39.07M |
| Long Term Debt | $73.72M | $74.41M | $72.78M | $72.82M | $71.96M | $53.67M | $59.12M | $64.55M | $69.08M | $72.78M | $73.15M | $73.56M | $73.89M | $68.26M | $56.04M | $60.27M | $65.58M | $62.48M | $67.11M | $72.43M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $1.21M | $1.20M | $1.19M | $1.24M | $1.23M | $1.23M | $1.22M | $1.24M | $1.23M | $1.22M | $1.22M | $1.23M | $1.22M | $2.28M | $192.52M | $189.93M | $187.42M | $183.03M | $182.21M | $188.87M |
| Total Non-Current Liabilities | $74.94M | $75.62M | $73.96M | $74.06M | $73.19M | $54.90M | $60.34M | $65.78M | $70.30M | $74.00M | $74.36M | $74.78M | $75.11M | $70.55M | $248.56M | $250.20M | $253.01M | $245.51M | $249.32M | $261.30M |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $148.36M | $150.05M | $135.19M | $135.31M | $147.76M | $137.44M | $131.75M | $128.25M | $128.69M | $131.60M | $130.68M | $122.16M | $131.56M | $124.50M | $315.99M | $308.66M | $302.14M | $290.26M | $287.37M | $300.37M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $49.00K | $49.00K | $49.00K | $48.00K | $48.00K | $47.00K | $47.00K | $47.00K | $47.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $46.00K | $45.00K | $45.00K | $45.00K | $40.00K |
| Retained Earnings | $-401.75M | $-386.19M | $-378.33M | $-370.33M | $-357.06M | $-347.27M | $-338.21M | $-333.10M | $-326.62M | $-322.45M | $-310.18M | $-295.34M | $-280.15M | $-266.41M | $-363.52M | $-347.27M | $-330.35M | $-311.79M | $-306.84M | $-298.61M |
| Accumulated Other Comprehensive Income Loss | $-1.03M | $-147.00K | $-569.00K | $-697.00K | $-993.00K | $-2.18M | $-2.61M | $-3.07M | $-4.10M | $-5.29M | $-4.34M | $-3.46M | $-948.00K | $-213.00K | $-87.00K | $-18.00K | $312.00K | $57.00K | $-96.00K | $-371.00K |
| Other Total Stockholders Equity | $863.71M | $851.31M | $840.94M | $827.29M | $824.17M | $812.24M | $803.20M | $790.97M | $787.42M | $778.01M | $771.18M | $761.58M | $764.81M | $755.05M | $748.64M | $738.48M | $742.39M | $729.22M | $723.75M | $526.30M |
| Total Stockholders Equity | $460.97M | $465.02M | $462.08M | $456.31M | $466.17M | $462.83M | $462.42M | $454.85M | $456.75M | $450.31M | $456.71M | $462.82M | $483.76M | $488.47M | $385.08M | $391.24M | $412.39M | $417.53M | $416.86M | $227.37M |
| Total Equity | $460.97M | $465.02M | $462.08M | $456.31M | $466.17M | $462.83M | $462.42M | $454.85M | $456.75M | $450.31M | $456.71M | $462.82M | $483.76M | $488.47M | $385.08M | $391.24M | $412.39M | $417.53M | $416.86M | $227.37M |
| Total Liabilities and Stockholders Equity | $609.33M | $615.07M | $597.27M | $591.63M | $613.93M | $600.27M | $594.17M | $583.10M | $585.45M | $581.91M | $587.39M | $584.98M | $615.31M | $612.97M | $701.08M | $699.90M | $714.54M | $707.80M | $704.23M | $527.73M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $609.33M | $615.07M | $597.27M | $591.63M | $613.93M | $600.27M | $594.17M | $583.10M | $585.45M | $581.91M | $587.39M | $584.98M | $615.31M | $612.97M | $701.08M | $699.90M | $714.54M | $707.80M | $704.23M | $527.73M |
| Total Investments | $- | $- | $7.99M | $40.99M | $52.98M | $52.42M | $67.38M | $84.08M | $114.52M | $125.23M | $128.19M | $153.77M | $179.77M | $184.96M | $162.02M | $150.95M | $216.45M | $216.20M | $159.31M | $46.77M |
| Total Debt | $76.53M | $77.13M | $75.32M | $75.36M | $74.49M | $74.38M | $74.83M | $75.22M | $69.08M | $74.81M | $74.97M | $75.32M | $75.65M | $72.84M | $74.53M | $73.58M | $74.00M | $74.55M | $74.81M | $76.04M |
| Net Debt | $-46.19M | $-53.21M | $-30.72M | $10.40M | $-9.82M | $-6.22M | $7.59M | $-2.12M | $10.98M | $25.99M | $20.41M | $47.18M | $31.99M | $32.96M | $6.92M | $-11.80M | $32.06M | $41.17M | $-13.71M | $54.27M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $- | $-30.44M | $-46.47M | $50.20M | $-48.16M |
| Depreciation and Amortization | $- | $14.81M | $11.71M | $10.44M | $9.55M |
| Deferred Income Tax | $- | $- | $- | $84.78M | $1.51M |
| Stock Based Compensation | $- | $35.73M | $28.77M | $28.08M | $22.64M |
| Change in Working Capital | $- | $-18.24M | $-18.88M | $-4.85M | $-6.64M |
| Accounts Receivables | $- | $- | $-8.99M | $-10.09M | $5.09M |
| Inventory | $- | $- | $-7.30M | $-4.27M | $-5.26M |
| Accounts Payables | $- | $6.18M | $2.68M | $4.71M | $-1.56M |
| Other Working Capital | $- | $-24.42M | $-5.26M | $4.80M | $-4.90M |
| Other Non Cash Items | $12.20M | $2.62M | $2.72M | $-182.43M | $1.22M |
| Net Cash Provided by Operating Activities | $12.20M | $4.48M | $-22.14M | $-13.78M | $-19.87M |
| Investments in Property Plant and Equipment | $- | $-12.00M | $-16.88M | $-9.75M | $-5.26M |
| Acquisitions Net | $- | $- | $-44.01M | $-33.26M | $- |
| Purchases of Investments | $- | $- | $-24.64M | $-173.10M | $-227.04M |
| Sales Maturities of Investments | $- | $63.81M | $85.52M | $206.36M | $75.31M |
| Other Investing Activities | $30.23M | $-30.00M | $44.01M | $33.26M | $800.00K |
| Net Cash Used for Investing Activities | $30.23M | $21.82M | $44.01M | $23.50M | $-156.20M |
| Debt Repayment | $-1.67M | $-992.00K | $-899.00K | $-816.00K | $-667.00K |
| Common Stock Issued | $- | $- | $- | $- | $188.96M |
| Common Stock Repurchased | $-6.95M | $-6.56M | $-12.20M | $-18.01M | $-13.03M |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $5.02M | $7.52M | $6.04M | $11.19M | $14.13M |
| Net Cash Used Provided by Financing Activities | $-3.60M | $-32.00K | $-7.06M | $-7.64M | $189.39M |
| Effect of Forex Changes on Cash | $-424.00K | $-58.00K | $-361.00K | $-372.00K | $136.00K |
| Net Change in Cash | $38.41M | $26.21M | $14.45M | $1.71M | $13.46M |
| Cash at End of Period | $122.72M | $84.31M | $58.10M | $43.65M | $41.94M |
| Cash at Beginning of Period | $84.31M | $58.10M | $43.65M | $41.94M | $28.48M |
| Operating Cash Flow | $12.20M | $4.48M | $-22.14M | $-13.78M | $-19.87M |
| Capital Expenditure | $- | $-42.00M | $-16.88M | $-9.75M | $-5.26M |
| Free Cash Flow | $12.20M | $-37.51M | $-39.02M | $-23.53M | $-25.13M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-15.57M | $-7.85M | $-8.01M | $-13.27M | $-9.79M | $-9.05M | $-5.12M | $-6.48M | $-4.17M | $-12.27M | $-14.84M | $-15.18M | $-13.74M | $97.11M | $-16.25M | $-16.92M | $-18.56M | $-4.95M | $-8.24M | $-16.41M |
| Depreciation and Amortization | $4.83M | $4.93M | $4.53M | $4.45M | $4.18M | $4.11M | $3.58M | $2.94M | $2.92M | $2.99M | $2.94M | $2.87M | $2.83M | $2.83M | $2.66M | $2.12M | $2.17M | $2.48M | $2.46M | $2.44M |
| Deferred Income Tax | $- | $- | $- | $- | $-22.36M | $167.00K | $125.00K | $- | $- | $- | $- | $- | $567.00K | $82.96M | $686.00K | $572.00K | $792.00K | $497.00K | $195.00K | $29.00K |
| Stock Based Compensation | $10.38M | $10.36M | $10.39M | $9.27M | $9.31M | $8.66M | $8.99M | $8.76M | $7.20M | $7.00M | $7.52M | $7.05M | $7.54M | $6.79M | $7.14M | $6.60M | $6.52M | $5.55M | $6.19M | $4.38M |
| Change in Working Capital | $-7.38M | $12.25M | $63.00K | $-23.30M | $-496.00K | $-2.97M | $-5.02M | $-9.76M | $-5.51M | $-696.00K | $7.72M | $-20.39M | $2.26M | $-822.00K | $-1.71M | $-4.58M | $8.26M | $-312.00K | $-5.09M | $-9.49M |
| Accounts Receivables | $-6.06M | $893.00K | $-342.00K | $-2.79M | $-932.00K | $-3.38M | $-2.66M | $-2.90M | $-4.00K | $-228.00K | $-807.00K | $-7.95M | $496.00K | $216.00K | $-4.10M | $-6.70M | $2.41M | $-2.45M | $-748.00K | $5.88M |
| Inventory | $831.00K | $-2.68M | $-1.74M | $-4.14M | $-5.79M | $-6.66M | $-6.53M | $-2.85M | $-1.59M | $-2.98M | $-793.00K | $-1.93M | $-465.00K | $-1.10M | $-1.44M | $-1.26M | $-519.00K | $-1.34M | $-674.00K | $-2.73M |
| Accounts Payables | $-5.77M | $4.25M | $-2.10M | $2.09M | $2.03M | $1.20M | $-121.00K | $3.07M | $-3.00M | $1.44M | $2.51M | $1.73M | $183.00K | $956.00K | $736.00K | $2.83M | $-1.04M | $1.46M | $-4.49M | $2.52M |
| Other Working Capital | $3.63M | $9.80M | $4.25M | $-18.46M | $4.20M | $5.87M | $4.29M | $-7.08M | $-914.00K | $1.08M | $-372.00K | $-12.23M | $2.05M | $-892.00K | $3.10M | $550.00K | $7.41M | $2.03M | $823.00K | $-15.16M |
| Other Non Cash Items | $13.57M | $311.00K | $24.90M | $23.98M | $23.19M | $606.00K | $449.00K | $450.00K | $-389.00K | $1.20M | $468.00K | $1.02M | $842.00K | $-189.10M | $2.94M | $2.88M | $4.78M | $548.00K | $-7.07M | $2.96M |
| Net Cash Provided by Operating Activities | $5.84M | $20.00M | $8.24M | $-21.88M | $4.03M | $1.52M | $3.01M | $-4.08M | $46.00K | $-1.78M | $4.23M | $-24.63M | $301.00K | $-232.00K | $-4.53M | $-9.32M | $3.95M | $3.81M | $-11.55M | $-16.09M |
| Investments in Property Plant and Equipment | $-2.69M | $-3.61M | $-2.38M | $-2.77M | $-2.79M | $-3.63M | $-33.08M | $-2.50M | $-4.17M | $-5.14M | $-4.18M | $-3.38M | $-2.71M | $-1.50M | $-4.21M | $-1.33M | $-1.05M | $-1.26M | $-1.11M | $-1.83M |
| Acquisitions Net | $- | $-25.00K | $25.00K | $- | $30.00M | $-30.00M | $- | $- | $-68.64M | $-1.91M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $15.50M | $-15.50M | $- | $- | $24.64M | $-20.70M | $-3.94M | $- | $-12.53M | $-65.76M | $-94.82M | $- | $-26.25M | $-73.73M | $-127.07M | $- |
| Sales Maturities of Investments | $- | $8.00M | $33.25M | $12.42M | $-63.81M | $15.50M | $17.00M | $31.32M | $11.17M | $22.60M | $28.65M | $23.10M | $16.32M | $42.16M | $82.97M | $64.91M | $25.32M | $16.25M | $14.57M | $19.16M |
| Other Investing Activities | $-12.00M | $25.00K | $33.27M | $12.42M | $-23.68M | $45.50M | $-13.00M | $31.32M | $44.01M | $1.91M | $24.70M | $23.10M | $3.79M | $-23.60M | $-94.82M | $64.91M | $-928.00K | $-57.47M | $800.00K | $19.16M |
| Net Cash Used for Investing Activities | $-14.69M | $4.39M | $30.89M | $9.64M | $-2.79M | $11.87M | $-16.08M | $28.81M | $7.00M | $-3.24M | $20.52M | $19.72M | $1.08M | $-25.10M | $-16.06M | $63.59M | $-1.98M | $-58.74M | $-112.81M | $17.33M |
| Debt Repayment | $-281.00K | $-269.00K | $-264.00K | $-855.00K | $-261.00K | $-248.00K | $-243.00K | $-240.00K | $-237.00K | $-225.00K | $-220.00K | $-217.00K | $1.45M | $-1.87M | $-201.00K | $-198.00K | $-199.00K | $-188.00K | $-186.00K | $-94.00K |
| Common Stock Issued | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $-192.00K | $-63.00K | $-159.00K | $-6.54M | $-84.00K | $-435.00K | $-299.00K | $-5.74M | $-65.00K | $-563.00K | $-938.00K | $-10.63M | $-111.00K | $-1.40M | $-1.40M | $-15.10M | $-100.00K | $-606.00K | $-547.00K | $-11.78M |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-3.42M | $- | $- | $- |
| Other Financing Activities | $2.21M | $-1.00K | $2.42M | $-470.00K | $2.70M | $815.00K | $3.54M | $462.00K | $2.28M | $383.00K | $3.02M | $355.00K | $1.17M | $1.01M | $4.42M | $4.59M | $6.75M | $493.00K | $2.85M | $4.04M |
| Net Cash Used Provided by Financing Activities | $1.74M | $-333.00K | $1.99M | $-7.00M | $2.36M | $132.00K | $2.99M | $-5.52M | $1.98M | $-405.00K | $1.86M | $-10.50M | $2.51M | $-2.26M | $2.82M | $-10.71M | $6.45M | $-301.00K | $191.07M | $-7.83M |
| Effect of Forex Changes on Cash | $-495.00K | $237.00K | $-57.00K | $-109.00K | $109.00K | $-166.00K | $-26.00K | $25.00K | $246.00K | $-305.00K | $-196.00K | $-106.00K | $-117.00K | $-140.00K | $13.00K | $-128.00K | $136.00K | $85.00K | $42.00K | $-127.00K |
| Net Change in Cash | $-7.61M | $24.30M | $41.07M | $-19.34M | $3.71M | $13.36M | $-10.10M | $19.24M | $9.28M | $-5.73M | $26.41M | $-15.51M | $3.77M | $-27.73M | $-17.76M | $43.44M | $8.56M | $-55.14M | $66.76M | $-6.72M |
| Cash at End of Period | $122.72M | $130.34M | $106.03M | $64.97M | $84.31M | $80.60M | $67.24M | $77.34M | $58.10M | $48.82M | $54.56M | $28.14M | $43.65M | $39.89M | $67.62M | $85.38M | $41.94M | $33.38M | $88.52M | $21.77M |
| Cash at Beginning of Period | $130.34M | $106.03M | $64.97M | $84.31M | $80.60M | $67.24M | $77.34M | $58.10M | $48.82M | $54.56M | $28.14M | $43.65M | $39.89M | $67.62M | $85.38M | $41.94M | $33.38M | $88.52M | $21.77M | $28.48M |
| Operating Cash Flow | $5.84M | $20.00M | $8.24M | $-21.88M | $4.03M | $1.52M | $3.01M | $-4.08M | $46.00K | $-1.78M | $4.23M | $-24.63M | $301.00K | $-232.00K | $-4.53M | $-9.32M | $3.95M | $3.81M | $-11.55M | $-16.09M |
| Capital Expenditure | $-14.69M | $-3.61M | $-2.38M | $-2.77M | $-2.79M | $-3.63M | $-33.08M | $-2.50M | $-4.17M | $-5.14M | $-4.18M | $-3.38M | $-2.71M | $-1.50M | $-4.21M | $-1.33M | $-1.05M | $-1.26M | $-1.11M | $-1.83M |
| Free Cash Flow | $-8.86M | $16.40M | $5.86M | $-24.65M | $1.24M | $-2.11M | $-30.07M | $-6.58M | $-4.12M | $-6.93M | $45.00K | $-28.01M | $-2.41M | $-1.74M | $-8.75M | $-10.64M | $2.90M | $2.55M | $-12.66M | $-17.92M |
AtriCure Dividends
Explore AtriCure's dividend history, including dividend yield, payout ratio, and historical payments.
AtriCure News
Read the latest news about AtriCure, including recent articles, headlines, and updates.
AtriCure to Host Analyst & Investor Day on March 26, 2025
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET. “Our team is excited to highlight our leading portfolio of products and innovative pipeline for market expa.
AtriCure, Inc. (ATRC) Q4 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lily Lozada - JPMorgan William Plovanic - Canaccord Matthew O'Brien - Piper Sandler Marie Thibault - BTIG Rick Wise - Stifel Mike Matson - Needham & Company Danny Stauder - Citizens JMP Danielle Antalffy - UBS Suraj Kalia - Oppenheimer Matthew O'Brien - Piper Sandler Operator Good afternoon, and welcome to AtriCure's Fourth Quarter and Full Year 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure Reports Fourth Quarter 2024 and Full Year 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced fourth quarter 2024 and full year 2024 financial results. “2024 was another outstanding year at AtriCure, marked by continued progress on driving growth, improving profitability, and the introduction of several meaningful product launches across our key fran.
Exploring Analyst Estimates for AtriCure (ATRC) Q4 Earnings, Beyond Revenue and EPS
Besides Wall Street's top -and-bottom-line estimates for AtriCure (ATRC), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.
AtriCure to Announce Fourth Quarter and Full Year 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its fourth quarter and full year 2024 financial results on Wednesday, February 12, 2025. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Wednesday, February 12, 2025, to discuss its fourth quarter and full year 2024 fin.
AtriCure to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. AtriCure's management is scheduled to present on Wednesday, January 15, 2025, at 3:00 pm Pacific Standard Time. Interested parties may access a live audio.
AtriCure, Inc. (ATRC) Q3 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q3 2024 Earnings Conference Call October 29, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan Mike Matson - Needham Danielle Antalffy - UBS Suraj Kalia - Oppenheimer & Co. Operator Good afternoon. And welcome to AtriCure's Third Quarter 2024 Earnings Conference Call.
AtriCure (ATRC) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended September 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure Reports Third Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2024 financial results. “Our broad-based growth in the third quarter reflects strong, ongoing adoption trends throughout our business,” said Michael Carrel, President and Chief Executive Officer at AtriCure. “During the quarter, we launched sev.
AtriCure Announces Launch of cryoSPHERE MAX™ Probe for Post-Operative Pain Management
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE MAX™ cryoablation probe. The cryoSPHERE MAX probe features a larger ball tip designed to optimize Cryo Nerve Block™ therapy (cryoNB). The new probe reduces freeze times by 50% when compared to AtriCure's first generation.
AtriCure to Announce Third Quarter 2024 Financial Results
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its third quarter 2024 financial results on Tuesday, October 29, 2024. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, October 29, 2024, to discuss its third quarter 2024 financial results. Those interested in.
Faisal Al Bannai
In 2023, the Advanced Technology Research Council (ATRC), an arm of the Abu Dhabi government, spent millions of dollars building a series of large language models. ATRC secretary general Faisal Al Bannai then decided to release them online for free, reasoning that if they were as good as the team’s internal testing showed, it would…
AtriCure Announces that the First Patient has been Treated with the Revolutionary AtriClip® FLEX-Mini™ Device
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the first patient was treated with the AtriClip® FLEX-Mini™ device, which recently received 510(k) clearance. The AtriClip FLEX-Mini sets a new standard as the smallest profile surgical LAA device on the market and builds upon the proven technology of.
AtriCure, Inc. (ATRC) Q2 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Michael Carrel - President and Chief Executive Officer Angela Wirick - Chief Financial Officer Conference Call Participants Lilia Lozada - JPMorgan John Newman - Canaccord Genuity John McAulay - Stifel Financial Corp. Sam Eiber - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Suraj Kalia - Oppenheimer & Co. Joseph Conway - Needham & Company Operator Good afternoon, And welcome to AtriCure's Second Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
AtriCure to Participate in the Canaccord Genuity 44th Annual Global Growth Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Canaccord Genuity 44th Annual Global Growth Conference. AtriCure's management is scheduled to present on Tuesday, August 13, 2024, at 10:30 am EST. Interested parties may access a live audio webcast of.
AtriCure to Participate in the 2024 Leerink Partners Healthcare Crossroads Conference
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Leerink Partners Healthcare Crossroads Conference. AtriCure's management is scheduled to participate in a fireside chat on Wednesday, May 29, 2024, at 10:40 a.m. Central Time. Interested parties may acc.
AtriCure, Inc. (ATRC) Q1 2024 Earnings Call Transcript
AtriCure, Inc. (NASDAQ:ATRC ) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Marissa Bych - Investor Relations Mike Carrel - President and Chief Executive Officer Angie Wirick - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan William Plovanic - Canaccord Genuity Marie Thibault - BTIG Danielle Antalffy - UBS Daniel Stauder - Citizens JMP Mike Matson - Needham & Company Suraj Kalia - Oppenheimer Operator Good afternoon and welcome to AtriCure's First Quarter 2024 Earnings Conference Call. This call is being recorded for replay purposes.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for ATRC.